Accurately determining the Market Size of the Leukapheresis Products Market is critical for investment decisions, as it directly reflects the total economic activity generated by cell-based therapies. The overall Market Size is calculated based on two core factors: the installed base of apheresis instruments globally and the annual volume of leukapheresis procedures performed. This volume has seen a significant upward revision due to the rapid commercialization of CAR T-cell therapies and the expanding number of clinical trials for other advanced cell and gene therapies (CGTs). Each commercial CGT product on the market translates into hundreds or thousands of required apheresis procedures annually, guaranteeing demand for the associated consumables.

Furthermore, the average price per disposable kit has been rising due to the introduction of technologically advanced, closed-system, and cell-specific collection products, which offer higher purity and lower contamination risk, thus contributing to an inflated total Market Size value. The therapeutic application of leukapheresis for conditions like hyperleukocytosis also adds a stable, non-discretionary revenue stream. The calculation must factor in both the capital expenditure for new machine purchases and the recurring revenue from the disposables. As more countries approve and reimburse cell therapies, the Market Size will continue to grow, positioning this sector as one of the most high-growth segments within the medical device industry. For a comprehensive quantification of the industry's economic value, refer to the Leukapheresis Products Market Size report.